Pfizer Broadens Portfolio Of Respiratory Vaccines Recommended By CDC Advisory Committee With ABRYSVO For RSV
Portfolio Pulse from Benzinga Newsdesk
Pfizer's ABRYSVO, a vaccine for respiratory syncytial virus (RSV), has been recommended by the CDC Advisory Committee for pregnant individuals between 32 and 36 weeks gestation. This recommendation expands Pfizer's portfolio of respiratory vaccines, which already includes vaccines for RSV in older adults, COVID-19, and pneumococcal pneumonia in adults.
September 22, 2023 | 7:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The CDC Advisory Committee's recommendation of Pfizer's ABRYSVO vaccine could potentially increase the company's market share in the respiratory vaccines sector.
The recommendation of ABRYSVO by the CDC Advisory Committee could lead to increased usage of the vaccine, potentially boosting Pfizer's revenues and market share in the respiratory vaccines sector. This is particularly relevant as the company already has a strong portfolio of respiratory vaccines.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100